

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss however arising from or in reliance upon the whole or any part of the contents of this announcement.



邁博藥業

Mabpharm Limited
迈博药业有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2181)

PROPOSED CHANGE OF AUDITOR

This announcement is made by Mabpharm Limited (the “**Company**”) pursuant to Rule 13.51(4) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The board of the directors (the “**Board**”) of the Company announces that Deloitte Touche Tohmatsu (“**Deloitte**”) will retire as auditor of the Company with effect from the conclusion of the forthcoming annual general meeting of the Company to be held on June 23, 2020 (the “**AGM**”).

The Company has recently conducted competitive negotiation for the selection of the Company’s auditor for the year ending December 31, 2020. On May 20, 2020, the Board resolved, based on the outcome of the competitive negotiation and with the recommendation from the audit committee of the Company, to propose an ordinary resolution at the AGM to approve the appointment of Ernst & Young as the auditor of the Company following the retirement of Deloitte, to hold office from the conclusion of the AGM to the conclusion of the next annual general meeting of the Company. This proposed appointment is subject to the approval of the shareholders of the Company at the AGM. In this connection, Deloitte, the current auditor of the Company, will retire as the auditor of the Company with effect from the conclusion of the AGM and will not be re-appointed.

The Board was not aware of any other matter regarding the proposed change of auditor that should be brought to the shareholders of the Company. The Company has received a confirmation letter dated May 20, 2020 from Deloitte confirming that there are no matters in relation to the proposed change of auditor that need to be brought to the attention of the shareholders of the Company.

The Board would like to express its appreciation to Deloitte for its services provided to the Company in the past years.

A circular containing, among other things, further details of the proposed change of auditor, together with a notice of the AGM, will be despatched to the shareholders of the Company in due course.

By order of the Board
Mabpharm Limited
Jiao Shuge
Chairman

Hong Kong, May 20, 2020

As at the date of this announcement, the Board of Directors comprises Dr. Qian Weizhu, Dr. Wang Hao, Mr. Li Yunfeng and Dr. Li Jing as executive Directors; Mr. Jiao Shuge and Mr. Guo Jianjun as non-executive Directors; and Mr. Guo Liangzhong, Dr. Zhang Yanyun and Dr. Liu Linqing as independent non-executive Directors.